Clarification9 Sept 2026, 05:20 pm
Senores Pharma Submits Corrigendum to FY26 Annual Report
AI Summary
Senores Pharmaceuticals Ltd has submitted a corrigendum to its Annual Report for the financial year 2025-26. This corrigendum addresses inadvertent typographical errors identified in the Narrative and Director's Report sections. The company assures that these corrections do not alter the substance or meaning of the disclosures. The revised report, incorporating these changes, will be available on the BSE, NSE, and the company's website. This corrigendum is being sent to shareholders to inform them of the minor amendments.
Key Highlights
- Corrigendum issued for FY25-26 Annual Report.
- Minor typographical errors corrected in specific sections.
- Substance of disclosures remains unchanged.
- Revised report to be available on exchange and company websites.
Price Impact
More from SENORES